Abstract
Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using β-blockers.
Keywords: COVID-19; cardiovascular medicine; drugs and medicines; infectious diseases.
All Keywords
【저자키워드】 COVID-19, Infectious diseases, cardiovascular medicine, drugs and medicines, 【초록키워드】 Treatment, Infectious diseases, Diseases, Antiviral, Remdesivir, cardiovascular disease, drug, ECG, Patient, hospitalisation, safety profile, bradycardia, during treatment, Medicines, β-blockers, receiving, baseline, cardiac monitoring, with COVID-19,
【저자키워드】 COVID-19, Infectious diseases, cardiovascular medicine, drugs and medicines, 【초록키워드】 Treatment, Infectious diseases, Diseases, Antiviral, Remdesivir, cardiovascular disease, drug, ECG, Patient, hospitalisation, safety profile, bradycardia, during treatment, Medicines, β-blockers, receiving, baseline, cardiac monitoring, with COVID-19,
{{{ 추상적인 }}}
렘데시비르는 입원이 필요한 코로나19 치료에 사용되는 항바이러스제다. 심혈관 안전성 프로파일에 대한 정보는 부족합니다. 우리는 remdesivir를 투여한 후 서맥이 발생한 COVID-19에 걸린 37세 남성의 사례를 보고합니다. 우리는 렘데시비르를 투여받기 전 모든 환자, 특히 기저 심혈관 질환이 있는 노인, 베타 차단제를 사용하는 환자의 지속적인 심장 모니터링과 지속적인 심장 모니터링을 위해 기준선 ECG를 권장합니다.
{{ 키워드: }} 코로나19; 심혈관 의학; 약물 및 의약품; 전염병.